Emerald Bioscience Inc. (
OTCMKTS:EMBI -
Get Free Report)'s stock price dropped 6.6% during mid-day trading on Monday . The company traded as low as $0.6467 and last traded at $0.6603. Approximately 307,414 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 14,236,620 shares. The stock had previously closed at $0.7070.
Emerald Bioscience Stock Performance
The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.59 and a current ratio of 3.59. The stock has a market cap of $177.01 million, a P/E ratio of -8.25 and a beta of 0.43.
About Emerald Bioscience
(
Get Free Report)
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Emerald Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emerald Bioscience wasn't on the list.
While Emerald Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
